Amisha Sarvesh Raikar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy

    by Amisha S. Raikar, Ananya Verma, Mayuri B. Naik, Sweta M. Prabhu, Keshav Raj Paudel, Kamal Dua

    Respiratory diseases are global health challenges demanding innovative immunotherapy solutions. Toll-like receptors (TLRs) play a crucial role in immune responses, making them attractive therapeutic targets. This review examines nanoparticle-based Toll-like receptor agonists as a promising approach for respiratory immunotherapy. Nanoparticles offer targeted drug delivery and sustained release, ideal for enhancing TLR agonist efficacy. This article explores TLRs' role in immunomodulation, nanoparticle applications, design considerations, preclinical efficacy, safety assessments, challenges, and future prospects. Promising results from animal studies suggest enhanced immunological responses and reduced inflammation compared to conventional treatments. Safety concerns are addressed with insights from toxicity studies. Challenges include regulatory hurdles and biocompatibility, with strategies proposed for optimization. Nanoparticle-based TLR agonists hold great potential to transform respiratory disease treatment, warranting further research and collaboration for successful clinical translation.

  • Open Access

    Formulation of Sertaconazole Nitrate-Based Pharmaceutical Systems for the Treatment of Onychomycosis

    by Shilpa. P. Bhilegaonkar, Purva. R. Laad, Hashweta Gawde, Amisha S. Raikar

    The study focused on developing transungual patches for the targeted treatment of onychomycosis, a common fungal infection of the nail. By incorporating Sertaconazole nitrate into patches using the Self-Microemulsifying Drug Delivery System (SMEDDS) technique, the aim was to overcome challenges related to drug penetration across the nail plate while enhancing solubility and permeability. Various patch formulations were prepared and extensively evaluated for key parameters such as thickness, weight variation, drug content, folding endurance, moisture content, moisture uptake, and in vitro drug release. The release data were analyzed using different kinetic models to understand the drug release mechanism. Selected formulations underwent accelerated stability testing per ICH guidelines, demonstrating stability under accelerated conditions. The study successfully addressed the challenges of transungual drug delivery, with the developed patches showing promising characteristics and stable release profiles. The application of kinetic models provided valuable insights, and the formulations passed stability testing, indicating their potential as effective and stable transungual drug delivery systems for the treatment of onychomycosis.

  • Top Cited Papers
    Open Access

    Neuromorphic computing for modeling neurological and psychiatric disorders: implications for drug development

    by Amisha S. Raikar, J Andrew, Pranjali Prabhu Dessai, Sweta M. Prabhu, Shounak Jathar, Aishwarya Prabhu, Mayuri B. Naik, Gokuldas Vedant S. Raikar

    The emergence of neuromorphic computing, inspired by the structure and function of the human brain, presents a transformative framework for modelling neurological disorders in drug development. This article investigates the implications of applying neuromorphic computing to simulate and comprehend complex neural systems affected by conditions like Alzheimer’s, Parkinson’s, and epilepsy, drawing from extensive literature. It explores the intersection of neuromorphic computing with neurology and pharmaceutical development, emphasizing the significance of understanding neural processes and integrating deep learning techniques. Technical considerations, such as integrating neural circuits into CMOS technology and employing memristive devices for synaptic emulation, are discussed. The review evaluates how neuromorphic computing optimizes drug discovery and improves clinical trials by precisely simulating biological systems. It also examines the role of neuromorphic models in comprehending and simulating neurological disorders, facilitating targeted treatment development. Recent progress in neuromorphic drug discovery is highlighted, indicating the potential for transformative therapeutic interventions. As technology advances, the synergy between neuromorphic computing and neuroscience holds promise for revolutionizing the study of the human brain’s complexities and addressing neurological challenges.


  • Open Access

    Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review

    by Amisha S. Raikar, Sushma Priya, Shilpa P. Bhilegaonkar, Sandesh N. Somnache, Deepak M. Kalaskar

    Cardiovascular diseases continue to be a major contributor to illness and death on a global scale, and the implementation of stents has given rise to a revolutionary transformation in the field of interventional cardiology. The thrombotic and restenosis complications associated with stent implantation pose ongoing challenges. In recent years, bioactive coatings have emerged as a promising strategy to enhance stent hemocompatibility and reduce thrombogenicity. This review article provides an overview of the surface engineering techniques employed to improve the hemocompatibility of stents and reduce thrombus formation. It explores the mechanisms underlying thrombosis and discusses the factors influencing platelet activation and fibrin formation on stent surfaces. Various bioactive coatings, including anticoagulant agents, antiplatelet agents, and surface modifications, are discussed in detail, highlighting their potential in reducing thrombogenicity. This article also highlights a multitude of surface modification techniques which can be harnessed to enhance stent hemocompatibility including plasma treatment, physical vapor deposition (PVD), chemical vapor deposition (CVD), and electrodeposition. These techniques offer precise control over surface properties such as roughness, charge, and composition. The ultimate goal is to reduce platelet adhesion, tailor wettability, or facilitate the controlled release of bioactive agents. Evaluation methods for assessing hemocompatibility and thrombogenicity are also reviewed, ranging from in vitro assays to animal models. Recent advances in the field, such as nanotechnology-based coatings and bioactive coatings with controlled drug release systems, are highlighted. Surface engineering of bioactive coatings holds great promise for enhancing the long-term outcomes of stent implantation by enhancing hemocompatibility and reducing thrombogenicity. Future research directions and potential clinical applications are discussed, underscoring the need for continued advancements in this field.


  • Open Access

    Surface Engineering of Bioactive Coatings for Improved Stent Hemocompatibility: A Comprehensive Review

    by Amisha S. Raikar, Sushma Priya, Shilpa P. Bhilegaonkar, Sandesh N. N Somnache, Deepak M. Kalaskar

    Cardiovascular diseases continuing to be a major contributor to illness and death on a global scale and the implementation of stents has given rise to a revolutionary transformation in the field of interventional cardiology. The thrombotic and restenosis complications associated with stent implantation pose ongoing challenges. In recent years, bioactive coatings have emerged as a promising strategy to enhance stent hemocompatibility and reduce thrombogenicity. This review article provides an overview of the surface engineering techniques employed to improve the hemocompatibility of stents and reduce thrombus formation. It explores the mechanisms underlying thrombosis and discusses the factors influencing platelet activation and fibrin formation on stent surfaces. Various bioactive coatings, including anticoagulant agents, antiplatelet agents, and surface modifications, are discussed in detail, highlighting their potential in reducing thrombogenicity. Evaluation methods for assessing hemocompatibility and thrombogenicity are also reviewed, ranging from in vitro assays to animal models. Recent advances in the field, such as nanotechnology-based coatings and bioactive coatings with controlled drug release systems, are highlighted. Surface engineering of bioactive coatings holds great promise for enhancing the long-term outcomes of stent implantation by enhancing hemocompatibility and reducing thrombogenicity. Future research directions and potential clinical applications are discussed, underscoring the need for continued advancements in this field.


  • Open Access

    Advances and Challenges in IoT-Based Smart Drug Delivery Systems: A Comprehensive Review

    by Amisha S. Raikar, Pramod Kumar, Gokuldas (Vedant) S. Raikar, Sandesh N. Somnache

    In the current era of technology, the internet of things (IoT) plays a vital role in smart drug delivery systems. It is an emerging field that offers promising solutions for improving the efficacy, safety, and patient compliance of drug therapies. IoT-based drug delivery systems leverage advanced devices, sophisticated sensors, and smart tools to monitor and analyse the health matrices of the patient in real-time, allowing for personalised and targeted drug delivery. This technology is implemented through various types of devices, including wearable and implantable devices such as infusion pumps, smart pens, inhalers, and auto-injectors. However, the development and implementation of IoT-based drug delivery systems pose several challenges, such as ensuring data security and privacy, regulatory compliance, compatibility, and reliability. In this paper, the latest research on smart wearable devices and its analysis are addressed. It also focuses on the challenges of ensuring the safe and efficient use of this technology in healthcare applications.


  • Open Access

    Advancements in artificial intelligence and machine learning in revolutionising biomarker discovery

    by Gokuldas (Vedant) Sarvesh Raikar, Amisha Sarvesh Raikar, Sandesh Narayan Somnache

    The article explores the significance of biomarkers in clinical research and the advantages of utilizing artificial intelligence (AI) and machine learning (ML) in the discovery process. Biomarkers provide a more comprehensive understanding of disease progression and response to therapy compared to traditional indicators. AI and ML offer a new approach to biomarker discovery, leveraging large amounts of data to identify patterns and optimize existing biomarkers. Additionally, the article touches on the emergence of digital biomarkers, which use technology to assess an individual’s physiological and behavioural states, and the importance of properly processing omics and multi-omics data for efficient handling by computer systems. However, the article acknowledges the challenges posed by AI/ML in the identification of biomarkers, including potential biases in the data and the need for diversity in data representation. To address these challenges, the article suggests the importance of regulation and diversity in the development of AI/ML algorithms.